Sotera Health CoSHC +1.64%74 PS Ratio is 4.19 as of Jun. 29, 2026, which is 1% below its 10-year median of 4.25. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 62.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sotera Health Co's share price is $17.375.
Sotera Health Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.15. Hence, Sotera Health Co's PS Ratio for today is 4.19.
The historical rank and industry rank for Sotera Health Co's PS Ratio or its related term are showing as below:
SHC'
s PS Ratio Range Over the Past 10 Years
Min: 1.7 Med: 4.25 Max: 9.29
Current: 4.19
During the past 8 years, Sotera Health Co's highest PS Ratio was 9.29. The lowest was 1.70. And the median was 4.25.
SHC's PS Ratio is ranked worse than 62.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.81
vs SHC: 4.19
During the past 12 months, the average Revenue per Share Growth Rate of Sotera Health Co was 6.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.80% per year.
During the past 8 years, Sotera Health Co's highest 3-Year average Revenue per Share Growth Rate was 5.00% per year. The lowest was 2.50% per year. And the median was 4.30% per year.
Back to Basics: PS Ratio
Sotera Health Co (NAS:SHC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Sotera Health Co PS Ratio Related Terms
Sotera Health Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sotera Health Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sotera Health Co's Share Price of today is $17.375. Sotera Health Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sotera Health Co (SHC) has a PS Ratio of 4.19 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sotera Health Co and its competitors. This is near median its historical median of 4.25. Over the past decade, Sotera Health Co's PS Ratio has ranged from 1.70 to 9.29. According to the industry distribution chart, Sotera Health Co ranks #125 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 62.5%.
Is Sotera Health Co's PS Ratio too high?
Sotera Health Co's current PS Ratio of 4.19 is near median its 10-year median of 4.25. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 9.29. The Medical Diagnostics & Research industry median PS Ratio is 2.81. Sotera Health Co's value of 4.19 is 49.1% above this industry median. Based on the distribution chart, Sotera Health Co ranks #125 out of 200 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's PS Ratio compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #125 out of 200 companies for PS Ratio. This places Sotera Health Co in the lower half of its industry. The industry median PS Ratio is 2.81. Sotera Health Co's value of 4.19 is 49.1% above this benchmark. Historically, Sotera Health Co's own PS Ratio has ranged from 1.70 to 9.29 over the past decade. While the company's 10-year median is 4.25 vs. the industry median of 2.81, Sotera Health Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current PS Ratio of 4.19 is 49.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current PS Ratio is 4.19, which is near median its own 10-year median of 4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.31, compared to a current price of $17.38 — trading 6.5% above its estimated fair value. The current PS Ratio is 4.19, which is near median its 10-year median of 4.25 and 49.1% above the Medical Diagnostics & Research industry median of 2.81. Sotera Health Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sotera Health Co (SHC), the current PS Ratio is 4.19 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.38 is trading 6.5% above its estimated GF Value™ of $16.31.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
PS Ratio: 4.19 (near median its 10-year median of 4.25)
GF Value™: $16.31 vs. price of $17.38 (6.5% above fair value)
Industry Position: 49.1% above the Medical Diagnostics & Research median (#125 of 200)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
